{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:59:31Z","timestamp":1772855971604,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Fluoroquinolone medications have been shown to contribute to tendinopathies, cardiotoxicity, and neurotoxicity. Low back pain is a common musculoskeletal condition for which chiropractic treatment is most often sought. This case report details a patient presenting with low back pain and a history of fluoroquinolone toxicity. The patient was initially treated with chiropractic manipulation, which increased her symptoms. She was then referred to an osteopathic physician who treated the patient with intravenous antioxidants and amino acids, an elimination diet, and probiotic supplementation. Within 4 months of therapy, the patient reported a decrease in pain, a resolution of her dizziness, shortness of breath, panic attacks, tachycardia, and blurred vision. After an additional 8 weeks of antioxidant therapy, she reported further reductions in pain and improved disability. People susceptible to fluoroquinolone toxicity may present with common musculoskeletal symptoms. A past medical history and medication history may help to identify this population of patients. People presenting with fluoroquinolone toxicity may have unidentified contributing factors that predispose them to this anomaly. This patient reported improvements in pain and disability following antioxidant amino acid therapy for a total of 6 months. The natural history of fluoroquinolone toxicity is unknown and may account for the observed improvements.<\/jats:p>","DOI":"10.4081\/cp.2012.e87","type":"journal-article","created":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T15:23:10Z","timestamp":1354116190000},"page":"e87","source":"Crossref","is-referenced-by-count":8,"title":["Fluoroquinolone Toxicity Symptoms in a Patient Presenting with Low Back Pain"],"prefix":"10.3390","volume":"2","author":[{"given":"Megan","family":"Strauchman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Morningstar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2012,11,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1345\/aph.1K605","article-title":"Interactions between warfarin and three commonly prescribed fluoroquinolones","volume":"42","author":"Carroll","year":"2008","journal-title":"Ann Pharmacother"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1185\/030079907X188099","article-title":"The safety profile of moxifl oxacin and other fluoroquinolones in special patient populations","volume":"23","author":"Iannini","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. an overview on mechanistic aspects","volume":"8","author":"De Sarro","year":"2001","journal-title":"Curr Med Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1086\/591126","article-title":"Emergency department visits for antibiotic-associated adverse events","volume":"47","author":"Shehab","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref5","first-page":"461","article-title":"Fluoroquinolone-associated tendinopathy","volume":"34","author":"Tsai","year":"2011","journal-title":"Chang Gung Med J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995\u20132002","volume":"118","author":"Linder","year":"2005","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00007632-199306000-00008","article-title":"Back pain in primary care. Outcomes at 1 year","volume":"18","author":"Von Korff","year":"1993","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00007632-200101010-00015","article-title":"Functional rating index: a new valid and reliable instrument to measure the magnitude of clinical change in spinal conditions","volume":"26","author":"Feise","year":"2001","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/humrep\/des038","article-title":"DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF","volume":"27","author":"Hanna","year":"2012","journal-title":"Hum Reprod"},{"key":"ref10","series-title":"Paper presented at the Conference on: Oxygen Metabolites in Nonheme Metabollichemistry, June 23, 1996","article-title":"Charge relay from molybdate oxyradicals to palladium-lipoic complex to DNA","author":"Garnett"},{"key":"ref11","first-page":"175","article-title":"Nutritional antioxidants and the modulation of inflammation: theory and practice","volume":"2","author":"Grimble","year":"1994","journal-title":"New Horiz"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pmrj.2010.10.003","article-title":"Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population","volume":"3","author":"Hall","year":"2011","journal-title":"PM R"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.genhosppsych.2007.11.003","article-title":"Levofloxacin-induced delirium with psychotic features","volume":"30","author":"Kiangkitiwan","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/106002809603000205","article-title":"Association of a Tourette-like syndrome with ofloxacin","volume":"30","author":"Thomas","year":"1996","journal-title":"Ann Pharmacother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.10359","article-title":"Seizures associated with fluoroquinolones","volume":"35","author":"Kushner","year":"2001","journal-title":"Ann Pharmacother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.aquatox.2011.08.022","article-title":"In vitro inhibition of cytochrome P450-mediated reactions by gemfibrozil, erythromycin, ciprofloxacin and fluoxetine in fish liver microsomes","volume":"109","author":"Smith","year":"2012","journal-title":"Aquat Toxicol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1345\/aph.1E587","article-title":"Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure","volume":"39","author":"Christie","year":"2005","journal-title":"Ann Pharmacother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jat.2717","article-title":"Epigenetic targets of some toxicologically relevant metals: a review of the literature","volume":"32","author":"Cheng","year":"2012","journal-title":"J Appl Toxicol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1155\/2012\/595307","article-title":"Nutritional manipulation of one-carbon metabolism: effects on arsenic methylation and toxicity","volume":"2012","author":"Hall","year":"2012","journal-title":"J Toxicol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3390\/ijms13032918","article-title":"Computational identification and modeling of crosstalk between Phosphorylation, O-\u03b2-glycosylation and Methylation of FoxO3 and implications for cancer therapeutics","volume":"13","author":"Butt","year":"2012","journal-title":"Int J Mol Sci"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/2\/4\/e87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:19:36Z","timestamp":1644473976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/2\/4\/e87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,28]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,12]]}},"alternative-id":["cp.2012.e87"],"URL":"https:\/\/doi.org\/10.4081\/cp.2012.e87","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,28]]}}}